meeting

Immutable Holdings Announces Voting Results for Its Annual General Meeting of Shareholders

TORONTO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Immutable Holdings Inc. (NEO:HOLD) (“Immutable Holdings” or the “Corporation”), a publicly-traded blockchain holding…

22 hours ago

Press Release: Sequana Medical announces results of Extraordinary General Meeting of Shareholders and update on Convertible Financing

Sequana Medical announces results of Extraordinary General Meeting of Shareholders and update on Convertible Financing Ghent, Belgium – 20 December…

2 days ago

Nova Leap Health Corp. provides update on Special Meeting

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Dec. 13, 2024…

1 week ago

Tessera Therapeutics Highlights Advances Across In Vivo Programs for Sickle Cell Disease and T-Cell Therapies at the 66th American Society of Hematology Annual Meeting

December 09, 2024 12:05 ET | Source: Tessera Therapeutics In vivo proof-of-concept achieved in humanized mice and non-human primates (NHPs)…

2 weeks ago

Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

December 09, 2024 12:00 ET | Source: Disc Medicine Inc  Positive updates across all programs, including updates from ongoing clinical…

2 weeks ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Poster presentation at ASH on Monday, December 9 at 6:00 p.m. PT / 9:00 p.m. ET CAMBRIDGE, Mass., Dec. 09,…

2 weeks ago

CRISPR Therapeutics Presents Data atthe 2024 American Society of Hematology (ASH) Annual Meeting

December 09, 2024 12:00 ET | Source: CRISPR Therapeutics AG -Preliminary data demonstrate that CTX112™ has the potential to provide…

2 weeks ago

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

December 08, 2024 12:30 ET | Source: C4 Therapeutics, Inc. In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest…

2 weeks ago

VivoPower to host Annual General Meeting on December 30, 2024 in London

London, Dec. 06, 2024 (GLOBE NEWSWIRE) -- VivoPower International PLC (NASDAQ: VVPR) (the “Company” or “VivoPower”) is pleased to announce…

2 weeks ago

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ and Its Impact on Blood Cancer Treatment Decisions

New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies…

2 weeks ago